UPDATED Mar 25, 2024
Companies in consumer staple industries including durables, food, beverage, tobacco, and household and personal products.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
LLY * | US$12,961.95 | 0.5% | 111.2% | US$696.4b | US$13,369.28 | PE132.9x | E27.2% | 0.7% | ||
NOVOB N | kr.2,128.92 | -6.1% | 62.3% | kr.4.0t | kr.2,164.42 | PE47.7x | E13.3% | 1.1% | ||
NVO N | kr.2,154.92 | -2.6% | 53.1% | kr.4.0t | kr.2,190.86 | PE47.7x | E13.3% | 1.1% | ||
JNJ * | US$2,593.00 | -1.4% | -6.3% | US$374.0b | US$2,927.58 | PE28.1x | E9.1% | 3.1% | ||
ABBV * | US$3,019.98 | -0.2% | 3.5% | US$316.0b | US$3,104.28 | PE65.6x | E23.1% | 3.5% | ||
MRK * | US$2,066.93 | 7.1% | 4.8% | US$313.7b | US$2,233.82 | PE869.5x | E24.5% | 2.5% | ||
TMO * | US$9,781.00 | -2.3% | -4.7% | US$222.3b | US$10,227.63 | PE36.5x | E10.5% | 0.3% | ||
NVS N | CHF1,606.00 | -6.8% | 5.7% | CHF189.2b | CHF1,820.54 | PE24.6x | E9.4% | 3.8% | ||
AZN N | UK£1,111.00 | -2.1% | -12.2% | UK£161.1b | UK£1,363.25 | PE34.2x | E16.5% | 2.2% | ||
ROG N | CHF4,459.55 | 0% | -14.0% | CHF180.9b | CHF5,567.56 | PE15.6x | E8.3% | 4.3% | ||
NOVN N | CHF1,719.29 | 0% | n/a | CHF180.4b | CHF1,885.96 | PE26.2x | E10.1% | 3.5% | ||
DHR * | US$4,258.85 | 0.4% | -6.6% | US$188.5b | US$4,481.42 | PE43.6x | E11.4% | 0.4% | ||
AZN1 N | UK£2,196.58 | 0% | -5.5% | UK£147.3b | UK£2,969.10 | PE31.2x | E17.5% | 2.4% | ||
PFE * | US$457.65 | -1.3% | -37.4% | US$155.3b | US$545.61 | PE72.8x | E20.6% | 6.1% | ||
AMGN * | US$4,610.00 | -0.8% | n/a | US$148.0b | US$4,992.60 | PE22.4x | E9.1% | 3.2% | ||
SAN1 N | €1,629.20 | 0% | -11.4% | €115.5b | €1,878.23 | PE12.7x | E5.7% | 3.9% | ||
SNY N | €804.15 | -0.4% | -16.2% | €111.9b | €965.39 | PE20.7x | E13.5% | 4.2% | ||
VRTX * | US$7,100.00 | 2.1% | 24.9% | US$107.5b | US$7,845.48 | PE29.7x | E11.2% | n/a | ||
BMY * | US$880.00 | 0.06% | -29.3% | US$105.7b | US$950.11 | PE13.2x | E7.8% | 4.6% | ||
REGN * | US$16,017.40 | 0% | 8.6% | US$103.9b | US$17,035.75 | PE26.1x | E9.6% | n/a | ||
CSL N | AU$3,635.42 | 0% | n/a | AU$145.0b | AU$4,103.81 | PE45.3x | E17.9% | 1.1% | ||
GILD * | US$1,230.70 | 0% | -16.0% | US$90.5b | US$1,465.29 | PE16x | E6.5% | 4.2% | ||
GSK1 N | UK£357.35 | 0% | n/a | UK£69.2b | UK£421.36 | PE14x | E9.4% | 3.4% | ||
GSK N | UK£706.98 | 0.8% | 4.7% | UK£69.2b | UK£829.78 | PE14.1x | E9.4% | 3.4% |